secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001607062-24-000150
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 8.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma issues 20,068 Series A Preferred shares for consulting; amends sublease
--------------------------------------------------------------------------------

- Issued 20,068 Series A Preferred shares to Value Quest Inc. for one-year social media consulting services.
- Consulting covers Facebook and Twitter management; shares are unregistered restricted securities.
- Amended sublease with BST Partners (controlled by CEO David Koos) to reimburse shared expenses in addition to $5k/month base rent.
- Subtenant also required to pay shared expenses retroactive to January 1, 2024, per amendment.
- Both transactions involve related party: David Koos is CEO and also controls BST Partners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000160706224000150/0001607062-24-000150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000160706224000150/rgbp042924form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-24-000150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer